EADV News: Roflumilast Cream 0.15% (Zoryve) Improves AD Across Diverse Skin Types
Roflumilast cream 0.15% (Zoryve, Arcutis) reduced lesion clearance and eased itch in individuals with atopic dermatitis (AD) regardless of race, ethnicity, and Fitzpatrick skin type, new pooled subgroup analysis results from the Phase 3 INTEGUMENT-1 and -2 trials. The results will be presented at the European Academy of Dermatology & Venereology (EADV) Congress in Amsterdam. […]